Literature DB >> 25714160

Burden of Clostridium difficile infection in the United States.

Fernanda C Lessa1, Yi Mu, Wendy M Bamberg, Zintars G Beldavs, Ghinwa K Dumyati, John R Dunn, Monica M Farley, Stacy M Holzbauer, James I Meek, Erin C Phipps, Lucy E Wilson, Lisa G Winston, Jessica A Cohen, Brandi M Limbago, Scott K Fridkin, Dale N Gerding, L Clifford McDonald.   

Abstract

BACKGROUND: The magnitude and scope of Clostridium difficile infection in the United States continue to evolve.
METHODS: In 2011, we performed active population- and laboratory-based surveillance across 10 geographic areas in the United States to identify cases of C. difficile infection (stool specimens positive for C. difficile on either toxin or molecular assay in residents ≥ 1 year of age). Cases were classified as community-associated or health care-associated. In a sample of cases of C. difficile infection, specimens were cultured and isolates underwent molecular typing. We used regression models to calculate estimates of national incidence and total number of infections, first recurrences, and deaths within 30 days after the diagnosis of C. difficile infection.
RESULTS: A total of 15,461 cases of C. difficile infection were identified in the 10 geographic areas; 65.8% were health care-associated, but only 24.2% had onset during hospitalization. After adjustment for predictors of disease incidence, the estimated number of incident C. difficile infections in the United States was 453,000 (95% confidence interval [CI], 397,100 to 508,500). The incidence was estimated to be higher among females (rate ratio, 1.26; 95% CI, 1.25 to 1.27), whites (rate ratio, 1.72; 95% CI, 1.56 to 2.0), and persons 65 years of age or older (rate ratio, 8.65; 95% CI, 8.16 to 9.31). The estimated number of first recurrences of C. difficile infection was 83,000 (95% CI, 57,000 to 108,900), and the estimated number of deaths was 29,300 (95% CI, 16,500 to 42,100). The North American pulsed-field gel electrophoresis type 1 (NAP1) strain was more prevalent among health care-associated infections than among community-associated infections (30.7% vs. 18.8%, P<0.001).
CONCLUSIONS: C. difficile was responsible for almost half a million infections and was associated with approximately 29,000 deaths in 2011. (Funded by the Centers for Disease Control and Prevention.).

Entities:  

Mesh:

Year:  2015        PMID: 25714160     DOI: 10.1056/NEJMoa1408913

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  828 in total

1.  Gastroenterologist perceptions of faecal microbiota transplantation.

Authors:  Sudarshan Paramsothy; Alissa J Walsh; Thomas Borody; Douglas Samuel; Johan van den Bogaerde; Rupert Wl Leong; Susan Connor; Watson Ng; Hazel M Mitchell; Nadeem O Kaakoush; Michael A Kamm
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

2.  Role of Coinfecting Strains in Recurrent Clostridium difficile Infection.

Authors:  Janet Sun; Tracy Mc Millen; N Esther Babady; Mini Kamboj
Journal:  Infect Control Hosp Epidemiol       Date:  2016-08-30       Impact factor: 3.254

3.  Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.

Authors:  David M Faleck; Hojjat Salmasian; E Yoko Furuya; Elaine L Larson; Julian A Abrams; Daniel E Freedberg
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

4.  Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.

Authors:  Michelle Hughes; Taha Qazi; Adam Berg; Janice Weinberg; Xinhua Chen; Ciaran P Kelly; Francis A Farraye
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

Review 5.  Host response to Clostridium difficile infection: Diagnostics and detection.

Authors:  Elena A Usacheva; Jian-P Jin; Lance R Peterson
Journal:  J Glob Antimicrob Resist       Date:  2016-09-20       Impact factor: 4.035

6.  Toxin A-negative toxin B-positive ribotype 017 Clostridium difficile is the dominant strain type in patients with diarrhoea attending tuberculosis hospitals in Cape Town, South Africa.

Authors:  B Kullin; J Wojno; V Abratt; S J Reid
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-30       Impact factor: 3.267

7.  An Evaluation of Food as a Potential Source for Clostridium difficile Acquisition in Hospitalized Patients.

Authors:  Jennie H Kwon; Cristina Lanzas; Kimberly A Reske; Tiffany Hink; Sondra M Seiler; Kerry M Bommarito; Carey-Ann D Burnham; Erik R Dubberke
Journal:  Infect Control Hosp Epidemiol       Date:  2016-10-03       Impact factor: 3.254

8.  Crystal structure of Clostridium difficile toxin A.

Authors:  Nicole M Chumbler; Stacey A Rutherford; Zhifen Zhang; Melissa A Farrow; John P Lisher; Erik Farquhar; David P Giedroc; Benjamin W Spiller; Roman A Melnyk; D Borden Lacy
Journal:  Nat Microbiol       Date:  2016-01-11       Impact factor: 17.745

Review 9.  Clostridium difficile colitis: pathogenesis and host defence.

Authors:  Michael C Abt; Peter T McKenney; Eric G Pamer
Journal:  Nat Rev Microbiol       Date:  2016-08-30       Impact factor: 60.633

10.  Bile Acid 7α-Dehydroxylating Gut Bacteria Secrete Antibiotics that Inhibit Clostridium difficile: Role of Secondary Bile Acids.

Authors:  Jason D Kang; Christopher J Myers; Spencer C Harris; Genta Kakiyama; In-Kyoung Lee; Bong-Sik Yun; Keiichi Matsuzaki; Megumi Furukawa; Hae-Ki Min; Jasmohan S Bajaj; Huiping Zhou; Phillip B Hylemon
Journal:  Cell Chem Biol       Date:  2018-10-25       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.